Compare Charles River Laboratories Intl. Inc (CRL) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Nucor Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $228.01 (market cap $11.14B), while Nucor Corporation trades at $234.69 (market cap $53.33B). The key difference: Nucor Corporation is far larger — about 4.8× Charles River Laboratories Intl. Inc's market cap, and Nucor Corporation pays a 0.96% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | NUE | |
|---|---|---|
Market Cap | $11.14B | $53.33B |
Sector | Health | Basic Materials |
52-Week High | $233.60 | $266.35 |
52-Week Low | $145.57 | $131.78 |
Enterprise Value | $14.00B | $57.97B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Nucor (NUE) trades at $233.00, up 2.48% over the past day, supported by a bullish technical signal and strong earnings beats in recent quarters. The stock benefits from a solid balance sheet with a debt-to-asset ratio of 20.23% (2025 company filing) and a 53-year dividend growth streak. Revenue for 2025 was $32.49 billion, with net income of $1.74 billion, though margins have compressed from peak levels. Recent news highlights a joint venture to address power infrastructure bottlenecks and positive analyst sentiment.
Outlook remains positive with a consensus price target of $262.89 (analyst reports July 2026), implying ~13% upside. Key opportunities include steel price strength and strategic expansions, but risks involve cyclical demand weakness and margin pressure. Institutional ownership trends and buy ratings (62.5% of analysts) support a constructive view, though investors should monitor Q2 2026 earnings for confirmation of guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
